Journal: International Journal of Cardiology. Cardiovascular Risk and Prevention

Article Title: Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis

doi: 10.1016/j.ijcrp.2026.200590

Figure Lengend Snippet: Summary of included studies.

Article Snippet: Clavijoa, 2023 , RCT, Double-blind , USA , 6 months , Evolocumab 420 mg SC q4w , placebo , 35 , 35 , 70 , Patients aged 40–85 years with a diagnosis of atherosclerotic cardiovascular disease and PAD (Rutherford class I-VI), confirmed by an ankle-brachial index (ABI) ≤0.9 at rest or ≤0.8 after exercise, angiography, duplex ultrasound, or a history of lower extremity surgical or endovascular revascularization. Patients had to be at least one month from their most recent intervention, stable on maximal tolerated lipid-lowering therapy for at least four weeks, and have a fasting LDL cholesterol ≥55 mg/dL or non-HDL cholesterol ≥80 mg/dL. , MWT at 6 months , After six months, Evolocumab significantly improved MWT, FMD, Carotid IMT, and plasma MRP-14 levels. In contrast, changes in pain-free walking time, ABI, TBI, transcutaneous oxygen pressure, oxLDL, and sCD36 were not statistically significant..

Techniques: Control, Biomarker Discovery, Clinical Proteomics, Activation Assay